Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype

Affiliations

11 January 2020

-

doi: 10.1177/1352458519881994


Abstract

Background: The Multiple Sclerosis Severity Score (MSSS) is a widely used measure of the disability progression rate. However, the global MSSS may not be the best basis for comparison between all patient groups.

Objective: We evaluated sex-specific and onset phenotype-specific MSSS matrices to determine if they were more effective than the global MSSS as a basis for comparison within these subsets.

Methods: Using a large international dataset of multiple sclerosis (MS) patient records and the original MSSS algorithm, we constructed global, sex-specific and onset phenotype-specific MSSS matrices. We compared matrices using permutation analysis.

Results: Our final dataset included 30,203 MS cases, with 28.9% males and 6.5% progressive-onset cases. Our global MSSS matrix did not differ from previously published data (p > 0.05). The progressive-onset-specific matrix differed significantly from the relapsing-onset-specific matrix (p < 0.001), with lower MSSS attributed to cases with the same Expanded Disability Status Score (EDSS) and disease duration. When evaluated with a simulation, using an onset-specific MSSS improved statistical power in mixed cohorts. There were no significant differences by sex.

Conclusion: The differences in the disability accrual rate between progressive- and relapsing-onset MS have a significant effect on MSSS. An onset-specific MSSS should be used when comparing the rate of disability progression among progressive-onset cases and for mixed cohorts.

Keywords: Multiple Sclerosis Severity Score; Multiple sclerosis; disability progression; onset phenotype.


Similar articles

Pediatric Multiple Sclerosis Severity Score in a large US cohort.

Santoro JD, Waltz M, Aaen G, Belman A, Benson L, Gorman M, Goyal MS, Graves JS, Harris Y, Krupp L, Lotze T, Mar S, Moodley M, Ness J, Rensel M, Rodriguez M, Schreiner T, Tillema JM, Waubant E, Weinstock-Guttman B, Hurtubise BF, Roalstad S, Rose J, Casper TC, Chitnis T; US Network of Pediatric MS Centers.Neurology. 2020 Sep 29;95(13):e1844-e1853. doi: 10.1212/WNL.0000000000010414. Epub 2020 Jul 20.PMID: 32690790 Free PMC article.

Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.

Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, Achiti I, Confavreux C, Coustans M, le Page E, Edan G, McDonnell GV, Hawkins S, Trojano M, Liguori M, Cocco E, Marrosu MG, Tesser F, Leone MA, Weber A, Zipp F, Miterski B, Epplen JT, Oturai A, Sørensen PS, Celius EG, Lara NT, Montalban X, Villoslada P, Silva AM, Marta M, Leite I, Dubois B, Rubio J, Butzkueven H, Kilpatrick T, Mycko MP, Selmaj KW, Rio ME, Sá M, Salemi G, Savettieri G, Hillert J, Compston DA.Neurology. 2005 Apr 12;64(7):1144-51. doi: 10.1212/01.WNL.0000156155.19270.F8.PMID: 15824338

Arylsulfatase a gene polymorphisms in relapsing remitting multiple sclerosis: genotype-phenotype correlation and estimation of disease progression.

Baronica KB, Mlinac K, Ozretić D, Vladić A, Bognar SK.Coll Antropol. 2011 Jan;35 Suppl 1:11-6.PMID: 21648305

Disability profile of MS did not change over 10 years in a population-based prevalence cohort.

Pittock SJ, Mayr WT, McClelland RL, Jorgensen NW, Weigand SD, Noseworthy JH, Rodriguez M.Neurology. 2004 Feb 24;62(4):601-6. doi: 10.1212/wnl.62.4.601.PMID: 14981177 Review.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010.PMID: 15089110 Review.


Cited by

Immune Cell Contributors to the Female Sex Bias in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis.

Alvarez-Sanchez N, Dunn SE.Curr Top Behav Neurosci. 2023;62:333-373. doi: 10.1007/7854_2022_324.PMID: 35467295

Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry Study.

Vitkova M, Diouf I, Malpas C, Horakova D, Kubala Havrdova E, Patti F, Ozakbas S, Izquierdo G, Eichau S, Shaygannejad V, Onofrj M, Lugaresi A, Alroughani R, Prat A, Larochelle C, Girard M, Duquette P, Terzi M, Boz C, Grand'Maison F, Sola P, Ferraro D, Grammond P, Butzkueven H, Buzzard K, Skibina O, Yamout BI, Karabudak R, Gerlach O, Lechner-Scott J, Maimone D, Bergamaschi R, Van Pesch V, Iuliano G, Cartechini E, José Sà M, Ampapa R, Barnett M, Hughes SE, Ramo-Tello CM, Hodgkinson S, Spitaleri DLA, Petersen T, Butler EG, Slee M, McGuigan C, McCombe PA, Granella F, Cristiano E, Prevost J, Taylor BV, Sãnchez-Menoyo JL, Laureys G, Van Hijfte L, Vucic S, Macdonell RA, Gray O, Olascoaga J, Deri N, Fragoso YD, Shaw C, Kalincik T; MSBase Study Group.Neurology. 2022 Jun 14;98(24):e2401-e2412. doi: 10.1212/WNL.0000000000200545. Epub 2022 Apr 11.PMID: 35410900 Free PMC article.

In Utero Exposure to Environmental Tobacco Smoke Increases Neuroinflammation in Offspring.

Durão ACCDS, Brandão WN, Bruno V, W Spelta LE, Duro SO, Barreto Dos Santos N, Paranhos BAPB, Zanluqui NG, Yonamine M, Pierre Schatzmann Peron J, Munhoz CD, Marcourakis T.Front Toxicol. 2022 Jan 17;3:802542. doi: 10.3389/ftox.2021.802542. eCollection 2021.PMID: 35295109 Free PMC article.

Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis.

Hanafin PO, Sermet-Gaudelus I, Griese M, Kappler M, Ellemunter H, Schwarz C, Wilson J, Tan M, Velkov T, Rao GG, Schneider-Futschik EK.Front Pharmacol. 2021 Aug 2;12:577263. doi: 10.3389/fphar.2021.577263. eCollection 2021.PMID: 34408649 Free PMC article.

Predisposing Factors for Sexual Dysfunction in Multiple Sclerosis.

Altmann P, Leutmezer F, Leithner K, Monschein T, Ponleitner M, Stattmann M, Rommer PS, Zrzavy T, Zulehner G, Berek K, Berger T, Bsteh G.Front Neurol. 2021 Feb 9;12:618370. doi: 10.3389/fneur.2021.618370. eCollection 2021.PMID: 33633671 Free PMC article.


KMEL References